Arovella Therapeutics (ALA) Corporate presentation summary

Investment highlights

• U.S. FDA IND accepted for ALA-101, with phase 1 trials for CD19-positive blood cancers expected in FY2026.

• Developing off-the-shelf iNKT cell therapies for blood and solid tumour cancers.

• Proprietary, clinic-ready manufacturing process for CAR-iNKT cells established.

• Strategic acquisitions and strong leadership with cell therapy expertise.

Financial overview

• Market capitalisation of $88.24 million as of May 2026, with $16.6 million cash on hand at March 2026.

• Share price ranged from $0.067 to $0.115 over the past year.

• Major shareholders include UBS Nominees and Netwealth Investments.

Leadership and advisory network

• Senior management and board have extensive drug development backgrounds.

• Scientific and clinical advisory boards include experts from leading cancer centers globally.